MedPath

Nicorandil

Generic Name
Nicorandil
Drug Type
Small Molecule
Chemical Formula
C8H9N3O4
CAS Number
65141-46-0
Unique Ingredient Identifier
260456HAM0
Background

Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .

Indication

Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.

Associated Conditions
Angina Pectoris

Dana-Farber Researchers Present Breakthrough Cancer Studies at AACR 2025 Annual Meeting

• Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30. • Key presentations include Phase 3 results of pembrolizumab in head and neck cancer, promising combination therapies for metastatic breast cancer, and novel RAS inhibitors showing efficacy in lung cancer patients. • The research spans innovative approaches including personalized cancer vaccines, targeted therapies for rare tumors, and digital health coaching interventions that demonstrate improved physical function in cancer survivors.
© Copyright 2025. All Rights Reserved by MedPath